MURANO Study Supports the Use of Fixed-Duration VenR in R/R CLL

Final 7-year follow-up findings from the MURANO study were revealed at this EHA 23’ congress. In this MEDtalk, professor of Translational Hematology, Arnon Kater, presents the results indicating meaningful progression-free survival of patients with relapsed/refractory chronic lymphatic leukemia (R/R CLL) treated with venetolax-rituximab (VenR).